
Malignant Lymphoma Market Trends
Malignant Lymphoma Market Research Report Information, by types (Hodgkin lymphoma and Non Hodgkin lymphoma), by treatment (chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others) - Forecast to 2035

Market Summary
As per Market Research Future Analysis, the malignant lymphoma market is projected to reach USD 8,365.4 Million by 2030, growing at a CAGR of 6.7% from 2022 to 2030. Lymphomas, prevalent forms of blood cancer, primarily affect men and are characterized by swollen glands. The market is driven by increasing clinical trials, rising cancer prevalence, and advancements in treatment options. However, high treatment costs and stringent regulations pose challenges. The COVID-19 pandemic has negatively impacted treatment accessibility, but recovery is anticipated as restrictions ease.
Key Market Trends & Highlights
Key trends influencing the malignant lymphoma market include advancements in treatment and increasing prevalence.
- Market expected to reach USD 8,365.4 Million by 2030 at a CAGR of 6.7%;
- Non-Hodgkin lymphoma predicted to dominate market share due to higher case prevalence;
- Immunotherapy segment holds significant market share, driven by products like Yescarta;
- North America accounts for the largest market share due to high prevalence and treatment awareness.
Market Size & Forecast
Market Size | USD 8,365.4 Million by 2030 |
CAGR | 6.7% from 2022 to 2030 |
Largest Regional Market Share | North America. |
Major Players
Key players include Amgen, Spectrum Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb, and Eli Lilly.
Market Trends
Drivers:
Increasing the clinical trials for developing the new drug candidates for various forms of lymphomas specifically for the harder treatment forms is anticipated to accelerate the growth of the market. The growing involvement of major companies in research and development leads to strong pipeline candidates that may propel market growth in the forecast period.
The rising prevalence of all forms of cancers including other types of blood cancers is one of the key driving factors of the market growth. The disease Lymphoma consists of a few blood cancer cases and there is a rise in demand for advanced products for the treatment. The essential thing was there are no clinical signs for the disease till it is in later stages. At this later stage, a more aggressive form of treatment is required for improved treatment outcomes. This factor is predicted to spur global market growth in the coming years.
Restraint:
Expensive treatment, complications related to drugs, low treatment options, and the presence of stringent regulatory guidelines are hampering the market growth.
Opportunities:
A rise in the number of improved diagnostic techniques and FDA approvals for therapy drugs may create an opportunity for key players to raise the market growth.
Challenges:
Due to the lower lymphoma treatment rates in emerging countries, the cost of the therapies becomes expensive which is reducing the number of individuals undergoing this treatment and most of the patients are not able to afford treatments like immunotherapies. Because the cost of these treatments is not affordable and accessible to poor people.
Study Objectives
To provide detailed information about the market structure along with many forecast segments and subsegments for the next 7 years.
To provide the factors that are impacting the growth of the market value.
To evaluate the malignant lymphoma market industry analysis based on porter’s five force analysis, factors-price analysis, etc.
To provide previous and forecast revenue segments and sub-segments of the market revenue for the four main geographies.
To offer the country-level analysis of the current market size and future prospective.
To provide country-level analysis of the global market industry growth by region, type, treatment, and application.
To provide a strategic profile of the prominent key competitors in the market, analyze their core competencies, and draw a global market growth landscape.
To track and analyze new product developments, joint ventures, strategic alliances, and global market research.
The Global Malignant Lymphoma Market is poised for growth, driven by advancements in targeted therapies and an increasing understanding of the disease's molecular underpinnings.
National Cancer Institute
Malignant Lymphoma Market Market Drivers
Rising Incidence of Malignant Lymphoma
The Global Malignant Lymphoma Market Industry is experiencing growth due to the increasing incidence of malignant lymphoma worldwide. According to health statistics, the prevalence of lymphoma cases has been on the rise, with an estimated 4.37 USD Billion market value in 2024. This surge is attributed to factors such as improved diagnostic techniques and heightened awareness among healthcare professionals and patients. As more individuals are diagnosed, the demand for effective treatment options escalates, thereby driving market expansion. The growing population and aging demographics further contribute to the increase in lymphoma cases, indicating a sustained need for innovative therapies in the Global Malignant Lymphoma Market Industry.
Market Segment Insights
Malignant Lymphoma Treatment Insights
Based on the treatment, the malignant lymphoma market is partitioned into various segments like radiation therapy, chemotherapy, immunotherapy, stem cell therapy, and others. Among them, the immunotherapy segment is holding a significant share due to the higher revenue realization of these drugs. Immunotherapies named Yescarta, a dominant product in this treatment is introduced by Kite Pharma, Inc.
Get more detailed insights about Malignant Lymphoma Market Research Report- Global Forecast To 2030
Regional Insights
Key Companies in the Malignant Lymphoma Market market include







Industry Developments
In May 2021, the popular enterpriser PerkinElmer, Inc is planning to acquire the Immunodiagnostic Systems Holdings PLC with an investment of nearly $155 million for expanding their overall diagnostics business.
In March 2020, one of the well-known companies Kura Oncology conducted a clinical trial for a pipeline candidate named tipifarnib which is used for the disease indication of peripheral T-cell lymphoma. Present, the clinical trial is in Phase-II and it received the fast track designation from the FDA.
In February 2021, the famous enterpriser Bristol Myers Squibb announced that their company received approval from the U.S Food and Drug Administration (FDA) for cancer immunotherapy as a treatment for adults who are having certain types of non-Hodgkin lymphoma.
Future Outlook
Malignant Lymphoma Market Future Outlook
The Global Malignant Lymphoma Market is projected to grow at a 9.27% CAGR from 2024 to 2035, driven by advancements in targeted therapies and increasing patient awareness.
New opportunities lie in:
- Invest in research for novel immunotherapies to enhance treatment efficacy.
- Develop digital health solutions for patient monitoring and engagement.
- Expand access to clinical trials in emerging markets to capture new patient demographics.
By 2035, the market is expected to demonstrate robust growth, reflecting advancements in treatment and increased global awareness.
Market Segmentation
Malignant Lymphoma Market Competitive Landscape
- Abbott Laboratories
- Actelion Pharmaceuticals
- Allos Therapeutics
- Bristol-Myers Squibb Company
- Celgene Corporation
- Genmab
- Roche
- Inovio Pharmaceuticals
- Johnson & Johnson
- Onyx Pharmaceuticals
- Seattle Genetics
- ABIOGEN PHARMA S.P.A
- Aeterna Zentaris, Inc
- Astellas Pharma
- Eli Lilly and Company
- Merck & Co. Inc
- Novartis
Report Scope
Attribute/Metric | Details |
Market Size | 8,365.4 Million |
CAGR (2022-2030) | 6.7% |
Base Year | 2021 |
Forecast Period | 2022-2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Types and treatment |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Abbott Laboratories, ABIOGEN PHARMA S.p.A., Actelion Pharmaceuticals, Aeterna Zentaris, Inc., Allos Therapeutics, Astellas Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genmab, Inovio Pharmaceuticals, Johnson & Johnson, and Merck & Co. Inc., Novartis, Onyx Pharmaceuticals, Roche, Seattle Genetics |
Key Market Opportunities | Technological advancement, macro economical and governing factors |
Key Market Drivers | Joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
How does the outlook of the global malignant lymphoma market look like?
The outlook of the global malignant lymphoma market looks very promising.
What are the major tailwinds pushing the growth of the global malignant lymphoma market?
Increased government funding for the drug development and increment in the global economy that is widening the access to quality care are the major tailwinds pushing the growth of the global malignant lymphoma market.
Which region holds the largest share in the global malignant lymphoma market?
North America holds the largest share in the global malignant lymphoma market, followed by Europe and the Asia Pacific, respectively.
Who are the top players in the global malignant lymphoma market?
Abiogen Pharma S.p.A., Abbott Laboratories, Genmab, Actelion Pharmaceuticals, Allos Therapeutics, Aeterna Zentaris, Inc., Novartis, Astellas Pharma, Seattle Genetics Johnson & Johnson, Celgene Corporation, Bristol-Myers Squibb Company, Roche, Merck & Co. Inc., Eli Lilly and Company, Inovio Pharmaceuticals, and Onyx Pharmaceuticals, are some of the major players operating in the malignant lymphoma market.
What are the key growth strategies of malignant lymphoma industry players?
Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global malignant lymphoma market adopt to gain a larger competitive advantage.
-
TABLE OF CONTENTS
-
1 INTRODUCTION
-
1.1 DEFINITION
-
1.2 SCOPE OF STUDY
-
1.2.1 RESEARCH OBJECTIVE
-
1.2.2 ASSUMPTIONS & LIMITATIONS
-
1.2.2.1 ASSUMPTIONS
-
1.2.2.2 LIMITATIONS
-
1.3 MARKET STRUCTURE:
-
2 RESEARCH METHODOLOGY
-
2.1 RESEARCH PROCESS:
-
2.2 PRIMARY RESEARCH
-
2.3 SECONDARY RESEARCH:
-
3 MARKET DYNAMICS
-
3.1 DRIVERS
-
3.2 RESTRAINTS
-
3.3 OPPORTUNITIES
-
3.4 MACROECONOMIC INDICATORS
-
4 MARKET FACTOR ANALYSIS
-
4.1 PORTERS FIVE FORCES MODEL
-
4.2 BARGAINING POWER OF SUPPLIERS
-
4.3 BARGAINING POWER OF BUYERS
-
4.4 THREAT OF NEW ENTRANTS
-
4.5 THREAT OF SUBSTITUTES
-
4.6 INTENSITY OF RIVALRY
-
5 GLOBAL MALIGNANT LYMPHOMA MARKET, BY TYPE
-
5.1 HODGKIN LYMPHOMA
-
5.2 NON-HODGKIN LYMPHOMA
-
GLOBAL MALIGNANT LYMPHOMA MARKET, BY
-
6.1 LYMPH NODES
-
6.2 BONE MARROW
-
6.3 SPLEEN
-
6.4 BLOOD
-
6.5 OTHER ORGANS
-
7. GLOBAL MALIGNANT LYMPHOMA MARKET, BY DIAGNOSTIC TESTS
-
7.1 IMMUNOPHENOTYPING
-
7.2 FLUORESCENCE IN SITU HYBRIDIZATION TESTING
-
7.3 FLOW CYTOMETER
-
8. GLOBAL MALIGNANT LYMPHOMA MARKET
-
8.1 CHEMOTHERAPY
-
8.2 RADIATION THERAPY
-
8.3 IMMUNOTHERAPY
-
8.4 STEM CELL THERAPY
-
8.5 OTHERS
-
9. GLOBAL MALIGNANT LYMPHOMA MARKET, BY REGION
-
9.1 INTRODUCTION
-
9.2 NORTH AMERICA
-
9.2.1 US
-
9.2.2 CANADA
-
9.3 EUROPE
-
9.3.1 WESTERN EUROPE
-
9.3.1.1 GERMANY
-
9.3.1.2 FRANCE
-
9.3.1.3 ITALY
-
9.3.1.3 SPAIN
-
9.3.1.5 UK
-
9.3.1.6 REST OF WESTERN EUROPE
-
9.3.2 EASTERN EUROPE
-
9.4 ASIA
-
9.4.1 JAPAN
-
9.4.2 CHINA
-
9.4.3 INDIA
-
9.4.4 AUSTRALIA
-
9.4.5 REPUBLIC OF KOREA
-
9.4.6 REST OF ASIA-PACIFIC
-
9.5 MIDDLE EAST & AFRICA
-
9.5.1 UNITED ARAB EMIRATES
-
9.5.2 SAUDI ARABIA
-
9.5.3 OMAN
-
9.5.4 KUWAIT
-
9.5.5 QATAR
-
9.5.6 REST OF MIDDLE EAST & AFRICA
-
10. COMPETITIVE LANDSCAPE
-
10.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
-
10.1.1 STRATEGIC PARTNERSHIP
-
10.1.2 MERGER & ACQUISITION
-
11 COMPANY PROFILE
-
11.1 ABBOTT LABORATORIES
-
11.1.1 OVERVIEW
-
11.1.2 PRODUCT OVERVIEW
-
11.1.3 FINANCIALS
-
11.1.4 KEY DEVELOPMENTS
-
11.2 ABIOGEN PHARMA
-
11.2.1 OVERVIEW
-
11.2.2 PRODUCT OVERVIEW
-
11.2.3 FINANCIALS
-
11.2.4 KEY DEVELOPMENTS
-
11.3 ACTELION PHARMACEUTICALS
-
11.3.1 OVERVIEW
-
11.3.2 PRODUCT OVERVIEW
-
11.3.3 FINANCIALS
-
11.3.4 STRATEGY
-
11.3.5 KEY DEVELOPMENT
-
11.4 ALLOS THERAPEUTICS
-
11.4.1 OVERVIEW
-
11.4.2 PRODUCT OVERVIEW
-
11.4.3 FINANCIALS
-
11.4.4 KEY DEVELOPMENTS
-
11.5 BRISTOL-MYERS SQUIBB COMPANY
-
11.5.1 OVERVIEW
-
11.5.2 PRODUCT OVERVIEW
-
11.5.3 FINANCIALS
-
11.5.4 KEY DEVELOPMENTS
-
11.6 OTHERS
Malignant Lymphoma Market Segmentation
Market Segmentation Overview
- Detailed segmentation data will be available in the full report
- Comprehensive analysis by multiple parameters
- Regional and country-level breakdowns
- Market size forecasts by segment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment